[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338867-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-338867-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","first-in-human-phase-i-study-of-minnelide-in-patients-with-advanced-gastrointestinal-cancers-safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity","First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers - Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity","","First-in-human, phase I evaluation of Minnelide, a water-soluble prodrug of triptolide, in patients with advanced gastrointestinal cancers to define safety, pharmacodynamics, antitumor activity, and the recommended phase II dose. Patients with refractory disease and measurable CT findings underwent 3+3 dose escalation with two scheduling strategies due to neutropenia-related toxicity; dose-limiting toxicities guided continuation until progression or unacceptable toxicity. Thirty-eight percent of adverse events involved neutropenia; antitumor signals included RECIST/Choi response and disease control rates.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/first-in-human-phase-i-study-of-minnelide-in-patients-with-advanced-gastrointestinal-cancers-safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity/338867/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/first-in-human-phase-i-study-of-minnelide-in-patients-with-advanced-gastrointestinal-cancers-safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity/338867.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is Minnelide and what is its rationale in cancer treatment?","Question",{"text":63,"@type":64},"Minnelide is a water-soluble prodrug of triptolide. Tripterolide is an anticancer agent designed to target cancer resistance through multiple mechanisms, including apoptosis-related pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the phase I study designed and how was the recommended phase II dose determined?",{"text":68,"@type":64},"The study used a 3+3 dose-escalation scheme in patients with refractory gastrointestinal carcinoma and measurable disease on CT. Two dosing schedules were evaluated due to neutropenia toxicity to identify the recommended phase II dose.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key safety findings and what toxicities were most common?",{"text":72,"@type":64},"Grade 3 or higher toxicities occurred in 69% of patients, with neutropenia being the most common (38%). Severe cerebellar toxicity was also observed in a small subset with higher triptolide exposure.",{"name":74,"@type":61,"acceptedAnswer":75},"What signs of antitumor activity were observed in this patient population?",{"text":76,"@type":64},"Overall response rate was 4%, while the disease control rate was 54% (15/28). Choi criteria showed a decrease in average tumor density in 57% (16/28) of patients.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},338867,1790197364,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity  \nErkut Borazanci*, 1,2, Ashok Saluja3, Jon Gockerman4, Mohana Velagapudi3, Ronald Korn1,5, Daniel Von Hoff1,2, Ed Greeno6  \n1 HonorHealth Research Institute, Scottsdale, AZ, USA 2Translational Genomics Research Institute (TGen), Phoenix, AZ, USA 3Minneamrita, Tampa, FL, USA  \n4 Novella Clinical, Morrisville, NC, USA 5 Imaging Endpoints, Scottsdale, AZ, USA 6Masonic Cancer Center, Minneapolis, MI, USA  \n* Corresponding author: Erkut Borazanci, MD, Oncology Division, HonorHealth Research Institute, 10510 N, 92nd St Suite 100, Scottsdale, AZ 85258, USA. Tel: +1 480-323-1350; Fax: +1 480-323-1359; Email: [eborazanci@honorhealth.com](eborazanci@honorhealth.com)  \nAbstract  \nBackground: Minnelide is a water-soluble prodrug of triptolide. Triptolide is an anticancer agent that targets cancer resistance through several mechanisms. Minnelide was evaluated in a phase I study in patients with advanced GI carcinomas to establish the safety, pharmacodynamic, antitumor activity, and recommended phase II dose (RP2D) .  \nPatients and Methods: Patients with refractory GI carcinoma and with measurable disease on CT scan were eligible. The study used a 3 + 3 dose-escalation scheme. Due to neutropenia toxicity, 2 dosing schedules were evaluated to determine the RP2D for future studies. Response was assessed using RECIST 1.1 and Choi criteria. Minnelide and triptolide PK were evaluated. Patients who completed the first 28-day treatment cycle without DLTs continued treatment until disease progression or unacceptable toxicity.  \nResults: Forty-five patients were enrolled (23 pancreatic cancer, 10 colorectal, and the remaining 9 had other GI tumors); 42 patients received at least one dose of Minnelide. Grade ≥ 3 toxicities occurred in 69% of patients, most common neutropenia (38%) . 2 patients with severe cerebellar toxicity who had a 2-fold higher triptolide concentration than other participants. ORR was 4%; the disease control rate (DCR) was 54%(15/28) . Choi criteria demonstrated a decrease in average tumor density in 57%(16/28) patients.  \nConclusions: This first-in-human, phase I clinical study identified a dose and schedule of Minnelide in patients with refractory GI cancers. The primary toxicity experienced was hematologic. Evidence of efficacy of Minnelide treatment in this group of patients was observed. The DCR ranged from ~2 to 6 months in 14/28 (50%) of evaluable patients. Studies in monotherapy and combination treatments are underway.  \nKey words: Minnelide; triptolide; gastrointestinal cancer; pancreatic cancer; gastric cancer.  \nImplications for Practice  \nWhile significant progress has been made to treat gastrointestinal (GI) cancers, there remains a need to look for additional therapeutic options. Minnelide is a novel compound that has been found to target HSP70 along with apoptosis, EMT, and transcription in malignancies. In a phase I study for refractory GI cancers Minnelide showed evidence of clinical benefit and is currently being explored in several clinical trials in oral formulation, both in single agent and in combination with other chemotherapeutic agents.  \nIntroduction  \nGastrointestinal (GI) tumors will account for over 169 000 deaths in the US in 2021,1 including >43 000 deaths from pancreatic cancer [Evan 2017] . Despite recent advances with systemic therapy, options remain limited upon resistance to chemotherapy. Several hallmarks of cancer contribute to chemotherapy resistance including cell  \ndeath by apoptosis; autophagy; reliance on the epithelialmesencyhmal transition (EMT) to invade, metastasize, and resist apoptosis; immune system modulation; and activation of key transcriptional pathways for growth [Hanahan 2011; Evan 2017] . New therapeutics are needed to improve survival rates for patients with metastatic gastrointestinal (GI) tumors.  \nReceived: 23 ","cbCaicIYcRKTfdwE","https://ap.wps.com/l/cbCaicIYcRKTfdwE","pdf",9912113,"English","# Background\n# Patients and Methods\n# Results\n# Conclusions\n# Implications for Practice\n# Introduction","[{\"question\":\"What is Minnelide and what is its rationale in cancer treatment?\",\"answer\":\"Minnelide is a water-soluble prodrug of triptolide. Tripterolide is an anticancer agent designed to target cancer resistance through multiple mechanisms, including apoptosis-related pathways.\"},{\"question\":\"How was the phase I study designed and how was the recommended phase II dose determined?\",\"answer\":\"The study used a 3+3 dose-escalation scheme in patients with refractory gastrointestinal carcinoma and measurable disease on CT. Two dosing schedules were evaluated due to neutropenia toxicity to identify the recommended phase II dose.\"},{\"question\":\"What were the key safety findings and what toxicities were most common?\",\"answer\":\"Grade 3 or higher toxicities occurred in 69% of patients, with neutropenia being the most common (38%). Severe cerebellar toxicity was also observed in a small subset with higher triptolide exposure.\"},{\"question\":\"What signs of antitumor activity were observed in this patient population?\",\"answer\":\"Overall response rate was 4%, while the disease control rate was 54% (15/28). Choi criteria showed a decrease in average tumor density in 57% (16/28) of patients.\"}]","First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers - Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity | PDF",1790026282,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c60ed75f5ab7cc0d92eee868aa6e5c9.webp",983,1291,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/160db6e5c507af0057bcb80d6f05eb15.webp",982,1290,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b7a2d33989fd2f3f5d6b2f50fcea826.webp",981,1289,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02a8b210b0c1ca22dd33cb33923d461e.webp",980,1287]